疏肝解郁胶囊联合阿戈美拉汀对抑郁症患者汉密尔顿抑郁量表评分及孤啡肽、白细胞介素-2的影响  

Effects of Shugan Jieyu Capsule(疏肝解郁胶囊)Combined with Agomelatine on HAMD Score and OFQ and IL-2 in Patients with Depression

作　　者：王萍 高朝 陈茹 代瑞甫 WANG Ping;GAO Zhao;CHEN Ru;DAI Ruifu(Hospital of The PLA Joint Service Support Force,Haikou 570100,Hainan,China)

机构地区：[1]中国人民解放军联勤保障部队第九二八医院,海南海口570100

出　　处：《中华中医药学刊》2024年第5期73-76,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：国家自然科学基金项目(81360512)。

摘　　要：目的探讨疏肝解郁胶囊联合阿戈美拉汀对抑郁症患者汉密尔顿抑郁量表(Hamilton Depression Scale,HAMD)评分及孤啡肽(Orphanin-FQ,OFQ)、白细胞介素-2(Interleukin-2,IL-2)的影响。方法收集诊治为抑郁症的患者90例,随机分为对照组与试验组,每组45例,对照组仅给予阿戈美拉汀口服治疗,试验组采用联合疗法,给予疏肝解郁胶囊联合阿戈美拉汀口服治疗,治疗3个月,观察治疗前后中医证候积分、HAMD评分及血清OFQ及IL-2变化,对治疗疗效进行评定。结果两组治疗前饮食、精神、大小便、夜寐、舌脉积分比较差异无统计学意义(P>0.05),治疗后较治疗前积分下降(对照组t=19.104、33.773、22.839、18.861、17.178,试验组t=43.690、48.830、45.737、39.032、31.847),且试验组下降幅度大于对照组(t=32.593、15.532、20.189、23.032、16.500),差异具有统计学意义(P<0.05)。两组治疗前HAMD评分比较差异无统计学意义(P>0.05),治疗后较治疗前评分下降(对照组t=5.531,试验组t=8.930),且试验组下降幅度大于对照组(t=5.360),差异具有统计学意义(P<0.05)。两组治疗前血清OFQ及IL-2水平比较差异无统计学意义(P>0.05),治疗后较治疗前血清OFQ及IL-2水平下降(对照组t=7.099、4.204,试验组t=13.099、7.411),且试验组下降幅度大于对照组(t=6.677、5.531),差异具有统计学意义(P<0.05)。试验组治疗总有效率为93.33%(42/45),高于对照组77.78%(35/45),差异具有统计学意义(P<0.05)。结论疏肝解郁胶囊联合阿戈美拉汀治疗抑郁症能明显降低HAMD评分及血清OFQ、IL-2水平,治疗疗效优于单用阿戈美拉汀,疗效肯定。Objective To investigate the effects of Shugan Jieyu Capsule(疏肝解郁胶囊)combined with agomelatine on Ham⁃ilton Depression Rating Scale(HAMD)score,orphanin enkephalin(OFQ)and interleukin-2(IL-2)in patients with depres⁃sion.Methods Ninety patients with depression diagnosed were randomly divided into the control group and the test group,with 45 patients in each group.The control group was only given oral treatment of agomelatine,and the test group was given Shugan Jieyu Capsule and agomelatine.The treatment lasted for 3 months.The TCM symptom score,HAMD score,serum OFQ and IL-2 changes before and after treatment were observed to evaluate the therapeutic effect.Results There was no statistical difference in the scores of diet,spirit,defecation,sleep,tongue or pulse between the two groups before treatment(P>0.05).After treatment,the scores of the two groups decreased compared with those before treatment(t=19.104,33.773,22.839,18.861,17.178 in the control group,t=43.690,48.830,45.737,39.032,31.847 in the test group),and the decline of the test group was greater than that of the control group(t=32.593,15.532,20.189,23.032,16.500),with statistical difference(P<0.05).There was no sta⁃tistical difference in HAMD score before treatment between two groups(P>0.05).After treatment,the score decreased compared with that before treatment(t=5.531 in the control group,t=8.930 in the test group),and the decrease in the test group was greater than that in the control group(t=5.360),with statistical difference(P<0.05).There was no statistical difference in ser⁃um levels of OFQ or IL-2 between the two groups before treatment(P>0.05).After treatment,the serum levels of OFQ and IL-2 decreased compared with those before treatment(t=7.099,4.204 in the control group,t=13.099,7.411 in the test group),and the decline range of the test group was greater than that of the control group(t=6.677,5.531),with statistical difference(P<0.05).The total effective rate of treatment in the test group was 93.33%(42/45),which was higher tha

关 键 词：疏肝解郁胶囊 阿戈美拉汀 抑郁症 汉密尔顿抑郁量表 孤啡肽 白细胞介素-2 

分 类 号：R277.7[医药卫生—中医学]